Latest Us Regulatory News

Page 4 of 9
Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.
Ada Torres
Ada Torres
4 Aug 2026
OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.
Ada Torres
Ada Torres
30 July 2026
Aurora Energy Metals progresses the Aurora Uranium Project with a major drill program imminent under Eagle Nuclear Energy, while broadening its Western Australian footprint with new exploration licences at Mukinbudin.
Maxwell Dee
Maxwell Dee
29 July 2026
Li-S Energy marked key commercial and regulatory milestones in Q2 2026, including ISO 9001:2015 certification for its lithium foil line, first commercial foil sale, and US air transport approvals for lithium-sulfur cells. The company also completed a major Battery Testing Centre expansion and began deep-ocean cell testing with MSubs.
Maxwell Dee
Maxwell Dee
24 July 2026
Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.
Ada Torres
Ada Torres
22 July 2026
Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.
Ada Torres
Ada Torres
13 July 2026
Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.
Ada Torres
Ada Torres
13 July 2026
Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.
Ada Torres
Ada Torres
7 July 2026
Argent BioPharma has struck a global licensing deal for its CannEpil® epilepsy therapy with Splash Beverage Group, securing US$5.5 million upfront through convertible debt forgiveness and retaining manufacturing and intellectual property rights alongside a 15% royalty on future sales.
Ada Torres
Ada Torres
7 July 2026
Barramundi Limited’s May update reveals a 2.3% adjusted NAV decline, weighed down by CSL’s earnings downgrade and Brambles’ operational setbacks, despite positive contributions from Xero and Credit Corp.
Claire Turing
Claire Turing
12 June 2026
OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.
Ada Torres
Ada Torres
9 June 2026
Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.
Victor Sage
Victor Sage
4 June 2026

Browse the archive

Full archive